Fig. 9: Association of peripheral immune cells with clinical benefit in mTNBC patients treated with atezolizumab with/without anthracycline-based chemotherapy. | npj Breast Cancer

Fig. 9: Association of peripheral immune cells with clinical benefit in mTNBC patients treated with atezolizumab with/without anthracycline-based chemotherapy.

From: Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation

Fig. 9

Forest plot showing odds ratios (OR). Clinical benefit was defined as patients who had either an objective response or stable disease lasting at least until the radiological evaluation at 24 weeks ± 7 days. Odds ratios were derived from univariate logistic regression. Unadjusted p-values are shown. Only factors with p-values < 0.05 in one or both treatment arms are shown. Atezo-Chemo; patients receiving combined Atezolizumab plus anthracycline-based chemotherapy (n = 29), Placebo-Chemo; patients receiving anthracycline-based chemotherapy only (n = 18).

Back to article page